Labcorp Finalizes Acquisition of Select Assets of Invitae

Core Insights - Labcorp has completed the acquisition of select assets from Invitae, enhancing its leadership in genetic testing solutions for oncology and select rare diseases [1][2] - The collaboration aims to leverage genetic insights to transform medicine, deliver personalized care, and improve health outcomes [2] Company Overview - Labcorp is a global leader in laboratory services, providing insights and advancing science to improve health through diagnostics and drug development capabilities [4] - The company employs over 67,000 individuals and serves clients in approximately 100 countries, supporting 84% of new drugs approved by the FDA in 2023 and conducting over 600 million tests globally [4] Acquisition Details - The acquisition will expand Labcorp's specialty testing capabilities and enhance its ability to utilize genetic data for improving clinical trials and treatment regimens [2] - By integrating Invitae's technology with Labcorp's capabilities, the company aims to provide a comprehensive set of insights for patients, covering testing, diagnosis, and treatment [2]